5月11日 - ** 疫苗制造商莫德纳（MRNA.O）的股价在盘前交易中上涨9%，至59.25美元
** 继上周五创下1月中旬以来最大单周涨幅后，Moderna股价有望延续涨势
** 上周，Moderna向路透透露，已与美国陆军传染病医学研究所合作，针对汉坦病毒 (link) 开展了临床前研究
** 莫德纳于2023年与高丽大学签署研究协议，将在其mRNA准入计划框架下合作开发汉坦病毒mRNA疫苗
** Inovio（INO.O）股价上涨11%，Novavax（NVAX.O）上涨4.3%
** 防护服制造商莱克兰工业（LAKE.O）和阿尔法普罗科技（APT.A）的股价在盘前交易中均上涨约6%
** 截至上一交易日收盘，mRNA今年以来累计上涨84.3%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.